Research Area
Tissue Repair & Regeneration
Tissue repair research peptides target multiple branches of the wound-healing cascade: extracellular matrix turnover, angiogenesis, fibroblast and keratinocyte signaling, and growth-factor release.
Research Use Only. All content on this page is for educational purposes. Compounds discussed are supplied solely for laboratory and research use. Where the active ingredient overlaps with an approved medication of the same name, the research compound is not the same product as any FDA-approved formulation containing the same active ingredient.
BPC-157 (the pentadecapeptide derived from a partial sequence of gastric body protein) and TB-500 (the synthetic acetylated tetrapeptide thymosin β4 1-4 fragment) are the two most-studied compounds in this area. Their characterized mechanisms differ — BPC-157 is associated with VEGFR2 / NO pathway signaling and tendon-to-bone collagen organization studies; TB-500 with actin sequestration and downstream angiogenesis — making them frequently studied side-by-side in comparative protocols.
GHK-Cu (glycyl-L-histidyl-L-lysine-Cu²⁺) is a copper-bound tripeptide originally isolated from human plasma. Research interest centers on its effects on dermal fibroblast gene expression, extracellular matrix remodeling, and copper-mediated antioxidant activity.
IGF-1 LR3 (Long R3 IGF-1) is a 70-amino-acid analog of human insulin-like growth factor 1 with extended half-life relative to native IGF-1; its arginine substitution at position 3 reduces IGF-binding-protein affinity. Studied as a growth-factor reference in cell-culture and skeletal-muscle hypertrophy research.
Compounds in this area
BPC-157: Synthetic Pentadecapeptide Research Overview
BPC-157 is a synthetic 15 amino acid peptide originally derived from a protective protein identified in gastric tissue. It has been studied across multiple preclinical research models examining cellular signaling, tissue integrity, and vascular pathway dynamics. This page summarizes the published research landscape for the compound, for laboratory and educational reference only.
Read research overview →
TB-500: Thymosin Beta-4 Fragment Research Overview
TB-500 is a synthetic peptide that corresponds to an active region of the naturally occurring 43-amino acid protein Thymosin Beta-4. It has been used in preclinical research as a tool compound for studying actin-binding protein interactions, cell migration patterns, and cytoskeletal signaling. This page summarizes the published research landscape on TB-500 and the laboratory models in which it has been characterized. For research and educational reference only.
Read research overview →
GHK-Cu: Copper Tripeptide Complex Research Overview
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) is one of the most extensively studied copper-binding peptides in preclinical research. The compound consists of three amino acids that together chelate a copper(II) ion. This page summarizes the published research on GHK-Cu's chemistry, mechanism studies, the laboratory models in which it has been characterized, and the analytical methods used to verify its identity and activity.
Read research overview →
IGF-1 LR3: Long R3 IGF-1 Analog Research Overview
IGF-1 LR3 (Long R3 IGF-1) is a synthetic modified analog of insulin-like growth factor 1 (IGF-1) with two structural changes: a 13-amino acid N-terminal extension and a substitution at position 3 (arginine replacing glutamate). These modifications reduce binding to IGF-binding proteins (IGFBPs), producing a research tool with altered pharmacokinetic and signaling behavior. This page summarizes the published preclinical literature.
Read research overview →
Ipamorelin: Selective Growth Hormone Secretagogue Research Overview
Ipamorelin is a synthetic pentapeptide developed as a selective ghrelin receptor (GHS-R1a) agonist for research applications. Unlike some growth hormone secretagogues that show off-target activity at other endocrine pathways, Ipamorelin demonstrates a comparatively narrow receptor profile in preclinical studies. This page summarizes the published research on its structural design, receptor selectivity, and laboratory characterization.
Read research overview →
CJC-1295 No DAC: Modified GHRH Analog Research Overview
CJC-1295 No DAC is a synthetic peptide based on the active 1-29 amino acid sequence of growth hormone-releasing hormone (GHRH), engineered with four amino acid substitutions to enhance enzymatic stability. The 'No DAC' designation distinguishes this variant from CJC-1295 with DAC, which includes an additional drug affinity complex linker for extended half-life. This page summarizes the published preclinical research on CJC-1295 No DAC's structure and laboratory applications.
Read research overview →
Related research areas
This page references compounds by their International Nonproprietary Name (INN) — the scientific designation used in PubMed and FDA literature. Brand-name medications are not referenced. All compounds are supplied as research-grade reference standards for laboratory and analytical use only.